Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?

Adewale Fawole, Rafat Abonour, Michael Stender, Seerin Shatavi, Susanna Gaikazian, Joseph Anderson, Ishmael Jaiyesimi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Asymptomatic (smoldering) multiple myeloma is a heterogeneous plasma cell proliferative disorder with a variable rate of progression to active multiple myeloma or related disorders. Hypercalcemia, renal insufficiency, anemia, bone lesions or recurrent bacterial infections characterize active multiple myeloma. Some patients with asymptomatic myeloma develop active disease rapidly, and others can stay asymptomatic for many years. Those who are likely to progress within the first 2 years of diagnosis have been categorized as having high-risk disease. The availability of novel agents in the treatment of active multiple myeloma and our better understanding of the heterogeneity of asymptomatic multiple myeloma have spurred interest in the early treatment of these patients. We have reviewed the current proposed definitions of high-risk asymptomatic multiple myeloma, the concerns about future therapy in view of the transient nature, remissions and toxicities of the therapies, and the eventual relapses that characterize this incurable disease.

Original languageEnglish
Pages (from-to)34-41
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Multiple Myeloma
Pharmaceutical Preparations
Therapeutics
Hypercalcemia
Plasma Cells
Bacterial Infections
Renal Insufficiency
Anemia
Bone and Bones
Recurrence

Keywords

  • Chemotherapeutic approaches
  • Cytogenetics
  • Myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma? / Fawole, Adewale; Abonour, Rafat; Stender, Michael; Shatavi, Seerin; Gaikazian, Susanna; Anderson, Joseph; Jaiyesimi, Ishmael.

In: Leukemia and Lymphoma, Vol. 56, No. 1, 01.01.2015, p. 34-41.

Research output: Contribution to journalArticle

Fawole, A, Abonour, R, Stender, M, Shatavi, S, Gaikazian, S, Anderson, J & Jaiyesimi, I 2015, 'Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?', Leukemia and Lymphoma, vol. 56, no. 1, pp. 34-41. https://doi.org/10.3109/10428194.2014.897702
Fawole, Adewale ; Abonour, Rafat ; Stender, Michael ; Shatavi, Seerin ; Gaikazian, Susanna ; Anderson, Joseph ; Jaiyesimi, Ishmael. / Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 1. pp. 34-41.
@article{51b4fbe7ebed487999686048f77d8065,
title = "Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?",
abstract = "Asymptomatic (smoldering) multiple myeloma is a heterogeneous plasma cell proliferative disorder with a variable rate of progression to active multiple myeloma or related disorders. Hypercalcemia, renal insufficiency, anemia, bone lesions or recurrent bacterial infections characterize active multiple myeloma. Some patients with asymptomatic myeloma develop active disease rapidly, and others can stay asymptomatic for many years. Those who are likely to progress within the first 2 years of diagnosis have been categorized as having high-risk disease. The availability of novel agents in the treatment of active multiple myeloma and our better understanding of the heterogeneity of asymptomatic multiple myeloma have spurred interest in the early treatment of these patients. We have reviewed the current proposed definitions of high-risk asymptomatic multiple myeloma, the concerns about future therapy in view of the transient nature, remissions and toxicities of the therapies, and the eventual relapses that characterize this incurable disease.",
keywords = "Chemotherapeutic approaches, Cytogenetics, Myeloma",
author = "Adewale Fawole and Rafat Abonour and Michael Stender and Seerin Shatavi and Susanna Gaikazian and Joseph Anderson and Ishmael Jaiyesimi",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/10428194.2014.897702",
language = "English",
volume = "56",
pages = "34--41",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?

AU - Fawole, Adewale

AU - Abonour, Rafat

AU - Stender, Michael

AU - Shatavi, Seerin

AU - Gaikazian, Susanna

AU - Anderson, Joseph

AU - Jaiyesimi, Ishmael

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Asymptomatic (smoldering) multiple myeloma is a heterogeneous plasma cell proliferative disorder with a variable rate of progression to active multiple myeloma or related disorders. Hypercalcemia, renal insufficiency, anemia, bone lesions or recurrent bacterial infections characterize active multiple myeloma. Some patients with asymptomatic myeloma develop active disease rapidly, and others can stay asymptomatic for many years. Those who are likely to progress within the first 2 years of diagnosis have been categorized as having high-risk disease. The availability of novel agents in the treatment of active multiple myeloma and our better understanding of the heterogeneity of asymptomatic multiple myeloma have spurred interest in the early treatment of these patients. We have reviewed the current proposed definitions of high-risk asymptomatic multiple myeloma, the concerns about future therapy in view of the transient nature, remissions and toxicities of the therapies, and the eventual relapses that characterize this incurable disease.

AB - Asymptomatic (smoldering) multiple myeloma is a heterogeneous plasma cell proliferative disorder with a variable rate of progression to active multiple myeloma or related disorders. Hypercalcemia, renal insufficiency, anemia, bone lesions or recurrent bacterial infections characterize active multiple myeloma. Some patients with asymptomatic myeloma develop active disease rapidly, and others can stay asymptomatic for many years. Those who are likely to progress within the first 2 years of diagnosis have been categorized as having high-risk disease. The availability of novel agents in the treatment of active multiple myeloma and our better understanding of the heterogeneity of asymptomatic multiple myeloma have spurred interest in the early treatment of these patients. We have reviewed the current proposed definitions of high-risk asymptomatic multiple myeloma, the concerns about future therapy in view of the transient nature, remissions and toxicities of the therapies, and the eventual relapses that characterize this incurable disease.

KW - Chemotherapeutic approaches

KW - Cytogenetics

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=84922361372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922361372&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.897702

DO - 10.3109/10428194.2014.897702

M3 - Article

VL - 56

SP - 34

EP - 41

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -